Last reviewed · How we verify
SSRI/Venlafaxine
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | SSRI/Venlafaxine |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | SSRI/Venlafaxine |
| Target | Serotonin transporter, Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By blocking the reuptake of serotonin and norepinephrine, venlafaxine increases the concentration of these neurotransmitters in the synaptic cleft, which can help alleviate symptoms of depression and anxiety. This is thought to occur through the inhibition of the serotonin and norepinephrine transporters, leading to increased synaptic levels of these neurotransmitters.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Dizziness
- Headache
- Insomnia
- Sweating
- Tremor
- Fatigue
- Dry mouth
- Constipation
- Diarrhea
Key clinical trials
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Neurobiological and Genomic Predictors of Relapse in Depression
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
- A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder (NA)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia (PHASE3)
- Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
- Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSRI/Venlafaxine CI brief — competitive landscape report
- SSRI/Venlafaxine updates RSS · CI watch RSS
- AstraZeneca portfolio CI